1. Home
  2. COOK vs TLSA Comparison

COOK vs TLSA Comparison

Compare COOK & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Traeger Inc.

COOK

Traeger Inc.

SELL

Current Price

$49.53

Market Cap

134.6M

ML Signal

SELL

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$0.93

Market Cap

145.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COOK
TLSA
Founded
1985
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Wholesale Distributors
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.6M
145.1M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
COOK
TLSA
Price
$49.53
$0.93
Analyst Decision
Hold
Analyst Count
5
0
Target Price
$53.00
N/A
AVG Volume (30 Days)
13.8K
598.6K
Earning Date
05-11-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$559,520,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.07
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.76
52 Week High
$86.59
$2.35

Technical Indicators

Market Signals
Indicator
COOK
TLSA
Relative Strength Index (RSI) 35.10 47.29
Support Level $47.15 $0.90
Resistance Level $77.25 $1.20
Average True Range (ATR) 2.41 0.09
MACD 0.12 -0.01
Stochastic Oscillator 14.19 63.08

Price Performance

Historical Comparison
COOK
TLSA

About COOK Traeger Inc.

Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Share on Social Networks: